Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as CDK inhibitors

A technology of drugs and compounds, applied in the field of compounds that inhibit the activity of selective transcriptional cyclin-dependent kinases, can solve problems such as failure

Active Publication Date: 2018-01-02
奥瑞基尼肿瘤学有限公司
View PDF20 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Confusingly, despite numerous attempts by the industry to find cell cycle-dependent changes in CDK7 kinase activity, they have been unsuccessful

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as CDK inhibitors
  • Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as CDK inhibitors
  • Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as CDK inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0386] Example 1: Synthesis of 1-acryloyl-N-(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrazolo[1,5-a][1 ,3,5]triazin-4-yl)amino)methyl)phenyl)piperidine-3-carboxamide (Compound 1).

[0387]

[0388] To a solution of 1-acryloylpiperidine-3-carboxylic acid (0.086 g, 0.47 mmol, Intermediate 12) in cooled DMF (4 mL) was added successively HATU (0.22 g, 0.59 mmol) at a temperature of 0 °C, DIPEA (0.2 mL, 1.18 mmol) and N4-(3-aminobenzyl)-8-isopropyl-N2-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a] [1,3,5]Triazine-2,4-diamine (0.15 g, 0.39 mmol, Intermediate 33). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with ice water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2x25 mL). The combined organic phases were washed with concentrated brine in Na 2 SO 4 Drying on celite, filtration and concentration gave a crude residue. Final...

Embodiment 2

[0395] Example 2: Synthesis of 1-acryloyl-N-(3-(((2-(((3R,4R)-3-fluoropiperidin-4-yl)amino)-8-isopropylpyrazolo[1,5- a] [1,3,5]Triazin-4-yl)amino)methyl)phenyl)pyrrolidine-3-carboxamide (Compound 14).

[0396] step 1: Synthesis of tert-butyl(3R,4R)-4-((4-((3-(1-acryloylpyrrolidine-3-carboxamido)benzyl) Amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-3-fluoropiperidine-1-carboxylate.

[0397]

[0398] To a solution of 1-acryloylpyrrolidine-3-carboxylic acid (0.05 g, 0.30 mmol, Intermediate 10) in cooled DMF (2 mL) was added successively HATU (0.11 g, 0.30 mmol) at a temperature of 0 °C, DIPEA (0.07mL, 0.40mmol) and tert-butyl(3R,4R)-4-((4-((3-aminobenzyl)amino)-8-isopropylpyrazolo[1,5-a] [1,3,5]Triazin-2-yl)amino)-3-fluoropiperidine-1-carboxylate (0.1 g, 0.20 mmol, intermediate 38). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with ice water and diluted with ethyl acetate. The aqueous layer was separa...

Embodiment 3

[0404] Example 3: Synthesis of 1-acryloyl-N-(3-(((8-isopropyl-2-(((S)-tetrahydro-2H-pyran-3-yl)amino)pyrazolo[1,5- a] [1,3,5]Triazin-4-yl)amino)methyl)phenyl)piperidine-2-carboxamide (Compound 16).

[0405] step 1: Synthesis of tert-butyl-2-((3-(((8-isopropyl-2-(((S)-tetrahydro-2H-pyran-3-yl)amino)pyridine Azolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamoyl)piperidine-1-carboxylate.

[0406]

[0407] To a solution of 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (0.13 g, 0.577 mmol) in cooled DMF (10 mL) was added sequentially HATU (0.26 g, 0.68 mmol) at a temperature of 0 °C, DIPEA (0.2 mL, 1.04 mmol) and (S)-N4-(3-aminobenzyl)-8-isopropyl-N2-(tetrahydro-2H-pyran-3-yl)pyrazolo[1, 5-a] [1,3,5]triazine-2,4-diamine (0.2 g, 0.524 mmol, intermediate 34). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with ice water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1, R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in amammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

Description

[0001] This application claims the benefit of Indian Provisional Patent Application (Application No: 1128 / CHE / 2015) filed March 9, 2015, the contents of which are hereby incorporated by reference. field of invention [0002] The present invention relates to compounds that inhibit the activity of selective transcriptional cyclin-dependent kinases (CDKs), said CDKs include CDK7, CDK9, CDK12, CDK13 and CDK18, especially represented by transcriptional cyclin-dependent kinase-7 (CDK7) . The invention also provides pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions to treat diseases or conditions associated with selectively transcribed CDKs. Background of the invention [0003] One of the most important and fundamental processes in biology is cell division mediated by the cell cycle. This process ensures that offspring cells with specific biological functions are produced under controlled conditions. It is a high...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/437
CPCA61K45/06C07D487/04A61K31/53A61P29/00A61P31/00A61P35/00A61P35/02A61P43/00
Inventor 苏姗塔·萨玛吉代尔拉姆鲁·波杜涂拉须伯汗杜·慕克吉拉杰夫·高斯瓦米
Owner 奥瑞基尼肿瘤学有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com